Melinda L. Telli, M.D.

5.0/5

Biography

Dr. Melinda Telli is Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, Director of the Breast Cancer Program and Associate Director of Clinical Research at the Stanford Cancer Institute and Associate Director of the Stanford Women's Cancer Center. Dr. Telli’s research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of ‘beyond BRCA’ DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.

Dr. Telli received her undergraduate degree from the University of Pennsylvania magna cum laude and medical degree from George Washington University with Distinction. She completed internship and residency in Internal Medicine at Stanford University, and then stayed at Stanford to pursue fellowship training in Medical Oncology. She has served on numerous American Society of Clinical Oncology Committees and currently serves as a Komen Scholar, Co-Chair of the ASCO Guideline Advisory Group, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and member of the Journal of Clinical Oncology Editorial Board. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Award (2008), American Society of Clinical Oncology Young Investigator Award (2009), Susan G. Komen for the Cure Leadership Award (2015-2024), Triple Negative Breast Cancer Foundation Hero Award (2018), Komen SF Bay Area Visionary Award (2019), and Stanford Medicine Increasing Access to Clinical Trials Star Award (2023). She has garnered multiple teaching accolades and is a repeat recipient of the Stanford Division of Oncology Teaching Award.

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Internal Medicine (2024)
Board Certification: American Board of Internal Medicine, Medical Oncology (2024)
B.A., University of Pennsylvania, Biology, with Distinction (1996)
- M.D., George Washington University, Medicine, with Distinction (2002)
- Residency, Stanford University, Internal Medicine (2005)
- Fellowship, Stanford University, Medical Oncology (2008)
- Board Certification, American Board of Internal Medicine, Internal Medicine (2015)
- Board Certification, American Board of Internal Medicine, Medical Oncology (2018)

View More Education & Certifications

Honors & Awards

Career Catalyst Research Award, Susan G. Komen for the Cure (2012)
Champion Award, Triple Step Toward the Cure (2015)
Fellow of the American Society of Clinical Oncology, American Society of Clinical Oncology (2024)
- Fellowship Award, Susan G. Komen for the Cure (2008)
- Hero Award, Triple Negative Breast Cancer Foundation (2018)
- Increasing Access to Cancer Clinical Trials Star Award, Stanford Medicine (2023)
- Komen Leadership Award, Susan G. Komen for the Cure (2015-2024)
- Merit Award, American Society of Clinical Oncology (2008)
- New Investigator Award, Stanford Cancer Institute (2011)
- Oncology Division Teaching Award, Stanford University School of Medicine (2010, 2012, 2013, 2014)
- San Francisco Bay Area Top Doctor, Medical Oncology, Castle Connolly (2017-2023)
- Visionary Award, Susan G. Komen San Francisco Bay Area (2019)
- Young Investigator Award, American Society of Clinical Oncology (2009)

View More Honors & Awards

Memberships

Editorial Board Member, Journal of Clinical Oncology (2017 - 2024)
Program Committee, AACR San Antonio Breast Cancer Symposium (2022 - 2024)
Co-Chair, American Society of Clinical Oncology Guideline Advisory Group (2021 - Present)
- Member, NRG Oncology Breast Committee (2023 - Present)
- Institutional PI, ECOG-ACRIN Research Group (2022 - Present)

View More Memberships

Administrative Appointments

ASCO Breast Cancer Adjuvant Chemotherapy and Targeted Therapy Guideline Adaptation Panel, American Society of Clinical Oncology (2015 - Present)
Associate Director of Clinical Research, Stanford Cancer Institute (2025 - Present)
Associate Director, Stanford Women's Cancer Center, Stanford Cancer Institute (2020 - Present)
- Breast Cancer Guidelines Panel, National Comprehensive Cancer Network (2014 - Present)
- Breast Cancer Maintenance of Certification Working Group, American Society of Clinical Oncology (2013 - 2014)
- Breast Oncology Protocol Review Committee Co-Chair, Stanford Cancer Institute (2015 - 2018)
- Director, Breast Cancer Program, Stanford Cancer Institute (2020 - Present)
- Komen Scholar, Susan G. Komen for the Cure (2015 - 2024)
- Leader, Breast Cancer Clinical Care Program, Stanford Medicine (2020 - Present)
- Leader, Breast Cancer Clinical Research Group, Stanford Cancer Institute (2018 - Present)
- Medical Oncology SEP Committee, American Board of Internal Medicine (2014 - 2017)
- Program Committee, ASCO Breast Cancer Symposium (2010 - 2013)
- Scientific Program Committee, Triple Negative Breast Cancer/Cytotoxics/Local Therapy, American Society of Clinical Oncology (2010 - 2013)
- Scientific Review Committee, Stanford Cancer Institute (2016 - Present)

View More Administrative Appointments

Publications

Phyllodes tumors of the breast: natural history, diagnosis, and treatment.
Telli, M. L., Horst, K. C., Guardino, A. E., Dirbas, F. M., & Carlson, R. W. (2007). Phyllodes tumors of the breast: natural history, diagnosis, and treatment. Journal of the National Comprehensive Cancer Network , 5(3), 324–30.
Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
Telli, M. L., Hunt, S. A., Carlson, R. W., & Guardino, A. E. (2007). Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility. JOURNAL OF CLINICAL ONCOLOGY, 25(23), 3525–33.
Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613–1618.
- First-Line Chemotherapy for Metastatic Breast Cancer
  Telli, M. L., & Carlson, R. W. (2009). First-Line Chemotherapy for Metastatic Breast Cancer. CLINICAL BREAST CANCER, 9, S66–S72.
- Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls
  Gramatges, M. M., Telli, M. L., Balise, R., & Ford, J. M. (2010). Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 19(2), 605–13.
- Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California
  Gomez, S. L., Lichtensztajn, D., Kurian, A. W., Telli, M. L., Chang, E. T., Keegan, T. H. M., … Clarke, C. A. (2010). Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California. JOURNAL OF CLINICAL ONCOLOGY, 28(10), E155–E157.
- Novel Treatment Approaches for Triple-Negative Breast Cancer
  Telli, M. L., & Ford, J. M. (2010). Novel Treatment Approaches for Triple-Negative Breast Cancer. CLINICAL BREAST CANCER, 10, E16–E22.
- Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry
  Telli, M. L., Chang, E. T., Kurian, A. W., Keegan, T. H. M., McClure, L. A., Lichtensztajn, D., … Gomez, S. L. (2011). Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. BREAST CANCER RESEARCH AND TREATMENT, 127(2), 471–78.
- Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?
  Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010). Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally? JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 56(20), 1644–50.
- PARP inhibitors in breast cancer.
  Telli, M. L., & Ford, J. M. (2010). PARP inhibitors in breast cancer. Clinical Advances in Hematology & Oncology : H&O, 8(9), 629–35.
- Trastuzumab-Related Cardiac Dysfunction
  Telli, M. L., & Witteles, R. M. (2011). Trastuzumab-Related Cardiac Dysfunction. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(2), 243–49.
- Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
  Witteles, R. M., Fowler, M. B., & Telli, M. L. (2011). Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented? HEART FAILURE CLINICS, 7(3), 333-?
- PARP inhibitors in cancer: moving beyond BRCA
  Telli, M. L. (2011). PARP inhibitors in cancer: moving beyond BRCA. LANCET ONCOLOGY, 12(9), 827–828.
- Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort
  Masciari, S., Dillon, D. A., Rath, M., Robson, M., Weitzel, J. N., Balmana, J., … Garber, J. E. (2012). Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. BREAST CANCER RESEARCH AND TREATMENT, 133(3), 1125–30.
- Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
  Witteles, R. M., & Telli, M. (2012). Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? JOURNAL OF CLINICAL ONCOLOGY, 30(16), 1916–18.
- Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
  Powell, A. A., Talasaz, A. A. H., Zhang, H., Coram, M. A., Reddy, A., Deng, G., … Jeffrey, S. S. (2012). Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines. PLOS ONE, 7(5).
- Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
  Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., Ganjoo, K., … Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939–42.
- Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer.
  Palesh, O., Peppone, L., Innominato, P. F., Janelsins, M., Jeong, M., Sprod, L., … Mustian, K. (2012). Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancer. Nature and Science of Sleep, 4, 151–62.
- Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells
  Yang, L. J., Guo, Y. L., Trygankova, O., Li, Q. Y., Maloney, J. A., Steinhauer, M., & Williamson, J. R. (1999). Epidermal growth factor and angiotensin II regulation of extracellular signal-regulated protein kinase in rat liver epithelial WB cells. BIOCHEMICAL PHARMACOLOGY, 57(4), 425–432.
- Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction A Chance That Cardiologists and Oncologists Should Not Miss Reply
  Witteles, R. M., Yoon, G., Telli, M., Kao, D. P., Matsuda, K. Y., & Carlson, R. W. (2011). Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction A Chance That Cardiologists and Oncologists Should Not Miss Reply. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 57(17), 1790–91.
- Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
  Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer. Journal of the American Medical Informatics Association , 20(6), 1059–66.
- Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer
  Telli, M. L. (2013). Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(29).
- A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk
  Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, B., McPherson, L., … Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. BREAST CANCER RESEARCH AND TREATMENT, electronic publication ahead of print, October 30.
- A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.
  Vinayak, S., Schwartz, E. J., Jensen, K., Lipson, J., Alli, E., McPherson, L., … Kurian, A. W. (2013). A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk. Breast Cancer Research and Treatment, 142(2), 389–98.
- Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer.
  Golden, D. I., Lipson, J. A., Telli, M. L., Ford, J. M., & Rubin, D. L. (2013). Qualitative and quantitative image-based biomarkers of therapeutic response in triple-negative breast cancer. AMIA Summits on Translational Science Proceedings AMIA Summit on Translational Science, 2013, 62-?
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
  Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., … Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. Breast Cancer Research , 16(2), R36-?
- Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.
  Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., … Jeffrey, S. S. (2014). Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer, 14, 456-?
- (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
  Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., & Gambhir, S. S. (2014). (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology, 273(2), 549–59.
- Optimizing chemotherapy in triple-negative breast cancer: the role of platinum.
  Telli, M. (2014). Optimizing chemotherapy in triple-negative breast cancer: the role of platinum. American Society of Clinical Oncology Educational Book / ASCO. American Society of Clinical Oncology. Meeting, 34, e37–42.
- Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition
  Zhang, H., Cohen, A. L., Krishnakumar, S., Wapnir, I. L., Veeriah, S., Deng, G., … Jeffrey, S. S. (2014). Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. BREAST CANCER RESEARCH, 16(2).
- Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow
  Deng, G., Krishnakumar, S., Powell, A. A., Zhang, H., Mindrinos, M. N., Telli, M. L., … Jeffrey, S. S. (2014). Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC CANCER, 14.
- F-18-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients
  Lagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., & Gambhir, S. S. (2014). F-18-FPPRGD2 PET/CT: Pilot Phase Evaluation of Breast Cancer Patients. RADIOLOGY, 273(2), 549–59.
- The future of breast cancer systemic therapy: the next 10 years.
  Telli, M. L., & Sledge, G. W. (2015). The future of breast cancer systemic therapy: the next 10 years. Journal of Molecular Medicine (Berlin, Germany), 93(2), 119–25.
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. Journal of Clinical Oncology , 33(17), 1895–1901.
- Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers
  Watkins, J., Weekes, D., Shah, V., Gazinska, P., Joshi, S., Sidhu, B., … Tutt, A. N. J. (2015). Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers. CANCER DISCOVERY, 5(5), 488–505.
- The role of platinum therapy in triple-negative breast cancer
  Afghahi, A., & Telli, M. L. (2014). The role of platinum therapy in triple-negative breast cancer. Breast Cancer Management, 3(4).
- Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
  Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J., … Ford, J. M. (2015). Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. JOURNAL OF CLINICAL ONCOLOGY, 33(17), 1895–U57.
- Breast Cancer, Version 1.2016.
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN, 13(12), 1475–85.
- Evolving treatment strategies for triple-negative breast cancer.
  Telli, M. (2015). Evolving treatment strategies for triple-negative breast cancer. Journal of the National Comprehensive Cancer Network , 13(5), 652–654.
- Breast Cancer Version 2.2015
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer Version 2.2015. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(4), 448–75.
- The role of platinum therapy in triple-negative breast cancer
  Afghahi, A., & Telli, M. L. (2014). The role of platinum therapy in triple-negative breast cancer . The Role of Platinum Therapy in Triple-Negative Breast Cancer , 3(4).
- Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
  Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., … Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. NATURE MEDICINE, 22(5), 547–56.
- Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
  Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., … Wolff, A. C. (2016). Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. JOURNAL OF CLINICAL ONCOLOGY, 34(20), 2416–U186.
- Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2016). Invasive Breast Cancer Version 1.2016 Clinical Practice Guidelines in Oncology. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 14(3), 324–54.
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
  Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., … Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical Cancer Research , 22(15), 3764–73.
- Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.
  Tsai, J., Bertoni, D., Hernandez-Boussard, T., Telli, M. L., & Wapnir, I. L. (2016). Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer. Annals of Surgical Oncology, 23(10), 3310–16.
- Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction.
  Weiskopf, K., Creighton, D., Lew, T., Caswell, J. L., Ouyang, D., Shah, A. T., … Telli, M. L. (2016). Acute, Unilateral Breast Toxicity From Gemcitabine in the Setting of Thoracic Inlet Obstruction. Journal of Oncology Practice / American Society of Clinical Oncology, 12(8), 763–64.
- Breast Cancer After Hodgkin Lymphoma: The Price of Success.
  Manzo, V., Dirbas, F., & Telli, M. L. (2016). Breast Cancer After Hodgkin Lymphoma: The Price of Success. Oncology (Williston Park, N.Y.), 30(12).
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
  Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M., Kaufman, B., Robson, M., … Shepherd, S. P. (2016). A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncology , -?
- Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance.
  Afghahi, A., Timms, K. M., Vinayak, S., Jensen, K. C., Kurian, A. W., Carlson, R. W., … Telli, M. L. (2017). Tumor BRCA1 Reversion Mutation Arising During Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Genetics of triple-negative breast cancer: Implications for patient care.
  Afghahi, A., Telli, M. L., & Kurian, A. W. (2016). Genetics of triple-negative breast cancer: Implications for patient care. Current Problems in Cancer, 40(2-4), 130–140.
- Genetics of triple-negative breast cancer: Implications for patient care
  Afghahi, A., Telli, M. L., & Kurian, A. W. (2016). Genetics of triple-negative breast cancer: Implications for patient care. CURRENT PROBLEMS IN CANCER, 40(2-4), 130–40.
- Reply to L. Del Mastro and A. Prat.
  Denduluri, N., Somerfield, M. R., Eisen, A., Holloway, J. N., Hurria, A., King, T. A., … Wolff, A. C. (2017). Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology , JCO2016709758-?
- Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer.
  Gruber, J. J., & Telli, M. L. (2017). Outstanding Questions in the Clinical Management of Triple-Negative Breast Cancer. Journal of Oncology Practice, 13(5), 305–7.
- A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
  Isakoff, S. J., Puhalla, S., Domchek, S. M., Friedlander, M., Kaufman, B., Robson, M., … Shepherd, S. P. (2017). A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. FUTURE ONCOLOGY, 13(4), 307–20.
- Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer.
  Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Telli, M. L., Kimmick, G., … Ellis, M. J. (2017). Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Non-amplified Metastatic Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- NCCN Guidelines Insights: Breast Cancer, Version 1.2017.
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2017). NCCN Guidelines Insights: Breast Cancer, Version 1.2017. Journal of the National Comprehensive Cancer Network , 15(4), 433–51.
- Breast Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Kumar, R. (2015). Breast Cancer, Version 1.2016 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 13(12), 1475–85.
- Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging.
  Banerjee, I., Malladi, S., Lee, D., Depeursinge, A., Telli, M., Lipson, J., … Rubin, D. L. (2018). Assessing treatment response in triple-negative breast cancer from quantitative image analysis in perfusion magnetic resonance imaging. Journal of Medical Imaging (Bellingham, Wash.), 5(1), 011008.
- Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study.
  Han, H. S., Diéras, V., Robson, M., Palácová, M., Marcom, P. K., Jager, A., … Puhalla, S. (2017). Veliparib With Temozolomide or Carboplatin/Paclitaxel Versus Placebo With Carboplatin/Paclitaxel in Patients With BRCA1/2 Locally Recurrent/Metastatic Breast Cancer: Randomized Phase II Study. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.
  Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC
  Vinayak, S., Newman, A., Adams, S., Afghahi, A., Jensen, K. C., Badve, S. S., … Telli, M. L. (2015). Deconvoluting immune cell populations using 'in silico flow cytometry' with CIBERSORT: Association with neoadjuvant therapy response and genomic instability in TNBC. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
  Kornblum, N., Zhao, F., Manola, J., Klein, P., Ramaswamy, B., Brufsky, A., … Sparano, J. A. (2018). Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017769331.
- Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology.
  Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., … Shead, D. A. (2018). Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 16(3), 310–20.
- Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
  Telli, M. L., Hellyer, J., Audeh, W., Jensen, K. C., Bose, S., Timms, K. M., … Ford, J. M. (2018). Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Research and Treatment, 168(3), 625–30.
- Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
  Doherty, M. R., Cheon, H. J., Junk, D. J., Vinayak, S., Varadan, V., Telli, M. L., … Jackson, M. W. (2017). Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 114(52), 13792–97.
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
  Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S., Hassett, M., … Giorando, S. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of Clinical Oncology.
- Exploiting Homologous Recombination Deficiency in TNBC
  Aleshin, A., & Telli, M. L. (2017). Exploiting Homologous Recombination Deficiency in TNBC. CURRENT BREAST CANCER REPORTS, 9(1), 52–59.
- Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer
  Telli, M. L., Stover, D., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., … Winer, E. P. (2018). Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research and Treatment.
- Genotype discordance between circulating tumor cells in blood and disseminated tumor cells in bone marrow at single cell level in breast cancer patients
  Deng, G., Krishnakumar, S., Coram, M. A., Powell, A. A., Zhang, H., Mindrinos, M. N., … Jeffrey, S. S. (2014). Genotype discordance between circulating tumor cells in blood and disseminated tumor cells in bone marrow at single cell level in breast cancer patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy.
  Kozak, M. M., Jacobson, C. E., von Eyben, R., Walck, E., Pollom, E. L., Telli, M., & Horst, K. C. (2018). Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy. Clinical Breast Cancer.
- Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer
  Kalinsky, K., Harding, J. J., DeMichele, A., Infante, J. R., Gogineni, K., Owonikoko, T. K., … Meric-Bernstam, F. (2018). Phase 1 study of CB-839, a first-in-class oral inhibitor of glutaminase, in combination with paclitaxel in patients with advanced triple negative breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)
  Telli, M. L., Lord, S., Dean, E., Abramson, V., Arkenau, H.-T., Murias, C., … Tolaney, S. M. (2018). ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response.
  Kozak, M. M., Jacobson, C. E., von Eyben, R., Pollom, E. L., Telli, M., & Horst, K. C. (2018). Outcomes Following Neoadjuvant Chemotherapy for Breast Cancer in Women Aged 40 Years and Younger: Impact of Pathologic Nodal Response. Journal of the National Comprehensive Cancer Network : JNCCN, 16(7), 845–50.
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
  Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., … Giordano, S. H. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018788604.
- Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
  Telli, M. L., Stover, D. G., Loi, S., Aparicio, S., Carey, L. A., Domchek, S. M., … Winer, E. P. (2018). Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research and Treatment.
- Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
  Cruz, C., Llop-Guevara, A., Garber, J. E., Arun, B. K., Perez Fidalgo, J. A., Lluch, A., … Isakoff, S. J. (2018). Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2018786558.
- 18F FPPRGD2 in breast cancer subjects: A novel PET radiopharmaceutical for imaging alpha v beta 3 integrin levels
  Iagaru, A., Mosci, C., Mittra, E., Shen, B., Chin, F., Chen, X., … Gambhir, S. (2011). 18F FPPRGD2 in breast cancer subjects: A novel PET radiopharmaceutical for imaging alpha v beta 3 integrin levels. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC.
- A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO).
  Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E.-M. M., … Robson, M. E. (2018). A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics.
  Quist, J., Mirza, H., Cheang, M. C., Telli, M. L., O'Shaughnessy, J., Lord, C. J., … Grigoriadis, A. (2018). A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics. Molecular Cancer Therapeutics.
- Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.
  Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S. S., Cortés, J., … Kim, S.-B. B. (2018). Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2017748392.
- Circulating tumor DNA and burden of disease in breast cancer
  Hoffman, A., Aleshin, A., Banks, K., Talasaz, A. A., Eltoukhy, H., Telli, M., & Wapnir, I. (2017). Circulating tumor DNA and burden of disease in breast cancer. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way.
  Telli, M. L., & Vinayak, S. (2019). Future of checkpoint blockade in triple-negative breast cancer: combination strategies to lead the way. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- NCCN Guidelines Insights: Breast Cancer, Version 3.2018.
  Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., … Kumar, R. (2019). NCCN Guidelines Insights: Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network : JNCCN, 17(2), 118–26.
- Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial.
  Hurvitz, S. A., Quek, R. G., Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., … Wardley, A. M. (2018). Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. European Journal of Cancer (Oxford, England : 1990), 104, 160–168.
- Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients.
  Kitani, T., Ong, S.-G. G., Lam, C. K., Rhee, J.-W. W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients. Circulation.
- Telomere length shortening in individuals with sporadic compared with familial breast cancer
  Gramatges, M., Telli, M., Balise, R., & Ford, J. (2009). Telomere length shortening in individuals with sporadic compared with familial breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105.
  Vinayak, S., Gray, R. J., Adams, S., Jensen, K. C., Manola, J., Afghahi, A., … Telli, M. L. (2014). Association of increased tumor-infiltrating lymphocytes (TILs) with immunomodulatory (IM) triple-negative breast cancer (TNBC) subtype and response to neoadjuvant platinum-based therapy in PrECOG0105. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance.
  Afghahi, A., Timms, K., Vinayak, S., Jensen, K. C., Chang, P.-J., Hartman, A.-R., … Telli, M. L. (2015). Association of tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based therapy in breast cancer (BC) with therapy resistance. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer
  Telli, M. L., Timms, K., Reid, J. E., Neff, C., Abkevich, V., Gutin, A., … Ford, J. M. (2015). Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer
  Telli, M. L., Audeh, W., Jensen, K. C., Bose, S., Timms, K., Gutin, A., … Ford, J. M. (2015). Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation-associated breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Multi-omic profiling to predict response to gemcitabine/ carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer using a pathway-based approach
  Vinayak, S., Benz, S. C., Vaske, C. J., Telli, M. L., & Ford, J. M. (2014). Multi-omic profiling to predict response to gemcitabine/ carboplatin (GC) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer using a pathway-based approach. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer
  Telli, M. L., Jensen, K. C., Kurian, A. W., Vinayak, S., Lipson, J. A., Schackmann, E. A., … Ford, J. M. (2013). PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC).
  Tannir, N. M., Fan, A. C., Lee, R. J., Carthon, B. C., Iliopoulos, O., Mier, J. W., … Bauer, T. M. (2018). Phase 1 study of glutaminase (GLS) inhibitor CB-839 combined with either everolimus (E) or cabozantinib (Cabo) in patients (pts) with clear cell (cc) and papillary (pap) metastatic renal cell cancer (mRCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer
  Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer. CIRCULATION, 139(21), 2451–65.
- Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy
  Kozak, M. M., Jacobson, C. E., von Eyben, R., Walck, E., Pollom, E. L., Telli, M., & Horst, K. C. (2018). Patterns of Distant Failure by Intrinsic Breast Cancer Subtype in Premenopausal Women Treated With Neoadjuvant Chemotherapy. CLINICAL BREAST CANCER, 18(5), E1077–E1085.
- Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer
  Afghahi, A., Purington, N., Han, S. S., Desai, M., Pierson, E., Mathur, M. B., … Kurian, A. W. (2018). Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer. CLINICAL CANCER RESEARCH, 24(12), 2851–58.
- Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC)
  Telli, M. L., Zablotsky, K., Gargosky, S. E., Twitty, C. G., & Wapnir, I. L. (2018). Intratumoral plasmid IL-12 and electroporation in pre-treated inoperable locally advanced or recurrent triple-negative breast cancer (TNBC). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- VISTA immune checkpoint deregulation in human triple-negative breast cancer
  Gruber, J. J., Juntilla, M. M., Yang, S.-R., Geller, B., Jager, N., Lin, C.-Y., … Snyder, M. P. (2018). VISTA immune checkpoint deregulation in human triple-negative breast cancer. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Induced Pluripotent Stem Cell-Based Cancer Vaccines
  Ouyang, X., Telli, M. L., & Wu, J. C. (2019). Induced Pluripotent Stem Cell-Based Cancer Vaccines. FRONTIERS IN IMMUNOLOGY, 10.
- Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines
  Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Allison, K. H., … Kumar, R. (2019). Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 17(2), 119–26.
- Induced Pluripotent Stem Cell-Based Cancer Vaccines.
  Ouyang, X., Telli, M. L., & Wu, J. C. (2019). Induced Pluripotent Stem Cell-Based Cancer Vaccines. Frontiers in Immunology, 10, 1510.
- Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC)
  Meric-Bernstam, F., Tannir, N. M., Mier, J. W., DeMichele, A., Telli, M. L., Fan, A. C., … Harding, J. J. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS), alone and in combination with everolimus (E) in patients (pts) with renal cell cancer (RCC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer.
  Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., … Telli, M. L. (2019). Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology.
- NCCN Guidelines Updates: Breast Cancer.
  Telli, M. L., Gradishar, W. J., & Ward, J. H. (2019). NCCN Guidelines Updates: Breast Cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 17(5.5), 552–555.
- Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
  Gruber, J. J., Afghahi, A., Hatton, A., Scott, D., McMillan, A., Ford, J. M., & Telli, M. L. (2019). Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
  Scott, D., Friedman, S., Telli, M. L., & Kurian, A. W. (2019). Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer. Journal of Oncology Practice, JOP1900221.
- CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
  Meric-Bernstam, F., Lee, R. J., Carthon, B. C., Iliopoulos, O., Mier, J. W., Patel, M. R., … Bauer, T. M. (2019). CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis.
  Telli, M. L., Chu, C., Badve, S. S., Vinayak, S., Silver, D. P., Isakoff, S. J., … Richardson, A. L. (2019). Association of Tumor Infiltrating Lymphocytes with Homologous Recombination Deficiency and BRCA1/2 Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction
  Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS.
- Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
  Gradishar, W. J., Anderson, B. O., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Kumar, R. (2020). Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 18(4), 452–78.
- A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS)
  Wapnir, I., DeMartini, W., Allison, K., Stone, K., Dirbas, F., Marquez, C., … Horst, K. (2020). A randomized phase II study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)
  Telli, M. L., Wapnir, I., Devitt, B., Cuff, K., Soliman, H., Vinayak, S., … Joshi, R. (2020). Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141). CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis
  Fernandez-Penas, P., Carlino, M., Atkinson, V., Telli, M., Joshi, R., Thomas, S., … Algazi, A. (2019). Intratumoral IL-12 plus pembrolizumab combination therapy in treatment refractory solid tumors: a safety and biomarker analysis. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMC.
- BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?
  Telli, M. L. (2020). BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer? The Lancet. Oncology.
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
  Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., … Harbeck, N. (2020). Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet (London, England), 396(10257), 1090–1100.
- Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants.
  Scott, D., Kingham, K., Hodan, R., Ma, C., Mills, M., Ford, J. M., … Telli, M. L. (2020). Clinicopathologic features of invasive breast cancer (BC) diagnosed in carriers of germline PALB2, CHEK2 and ATM pathogenic variants. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy.
  Telli, M. L., Nagata, H., Wapnir, I. L., Acharya, C., Zablotsky, K. E., Fox, B. A., … Crosby, E. J. (2021). Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- INTRATUMORAL PLASMID IL-12 EXPANDS CD8+T CELLS AND INDUCES A CLINICALLY VALIDATED CXCR3 SIGNATURE IN TRIPLE-NEGATIVE BREAST CANCER
  Crosby, E., Nagata, H., Telli, M., Acharya, C., Wapnir, I., Zablotsky, K., … Lyerly, H. (2020). INTRATUMORAL PLASMID IL-12 EXPANDS CD8+T CELLS AND INDUCES A CLINICALLY VALIDATED CXCR3 SIGNATURE IN TRIPLE-NEGATIVE BREAST CANCER. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.
- Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations
  Gruber, J. J., Afghahi, A., Hatton, A., Gross, W., Foran, J., McMillan, A., … Telli, M. L. (2021). Genomic analysis from the talazoparib beyond BRCA clinical trial: Homologous recombination (HR) deficiency scores, loss-of-heterozygosity and mutations in non-BRCA1/2 mutant tumors with other HR mutations. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients
  Crosby, E. J., Nagata, H., Telli, M. L., Acharya, C. R., Wapnir, I., Zablotsky, K., … Lyerly, H. K. (2021). Intratumoral delivery of tavokinogene telseplasmid (plasmid IL-12) and electroporation induces an immune signature that predicts successful combination in patients. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
  Vahdat, L. T., Schmid, P., Forero-Torres, A., Blackwell, K., Telli, M. L., Melisko, M., … Yardley, D. A. (2021). Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. NPJ Breast Cancer, 7(1), 57.
- NCCN Guidelines Insights: Breast Cancer, Version 4.2021.
  Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Kumar, R. (2021). NCCN Guidelines Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network : JNCCN, 19(5), 484–493.
- Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors.
  Harding, J. J., Telli, M. L., Munster, P. N., Le, M. H., Molineaux, C., Bennett, M. K., … Infante, J. R. (2015). Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors.
  Harding, J. J., Telli, M., Munster, P., Voss, M. H., Infante, J. R., DeMichele, A., … Meric-Bernstam, F. (2021). A Phase 1 Dose-Escalation and Expansion Study of Telaglenastat in Patients With Advanced or Metastatic Solid Tumors. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy
  Cruz, C., Llop-Guevara, A., Garber, J. E., Arun, B. K., Perez Fidalgo, J. A., Lluch, A., … Isakoff, S. J. (2018). Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. JOURNAL OF CLINICAL ONCOLOGY, 36(31), 3134-+.
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
  Tutt, A. N., Garber, J. E., Kaufman, B., Viale, G., Fumagalli, D., Rastogi, P., … Geyer, C. E. (2021). Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. The New England Journal of Medicine, 384(25), 2394–2405.
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update.
  Denduluri, N., Somerfield, M. R., Chavez-MacGregor, M., Comander, A. H., Dayao, Z., Eisen, A., … Giordano, S. H. (2021). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(6), 685–693.
- Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
  Telli, M. L., Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Mina, L. A., … Blum, J. L. (2021). Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.
  Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Blum, J. L., Mina, L. A., … Telli, M. L. (2021). Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.
  Gruber, J. J., Gross, W., McMillan, A., Ford, J. M., & Telli, M. L. (2021). A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial.
  Meric-Bernstam, F., Tannir, N. M., Lliopoulos, O., Lee, R. J., Telli, M. L., Fan, A. C., … Bauer, T. M. (2022). Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research.
- Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin plus /- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
  Telli, M. L., Metzger, O., Timms, K., Evans, B., Vogel, D., Wei, H., … Golshan, M. (2018). Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin plus /- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
  Henry, N. L., Somerfield, M. R., Dayao, Z., Elias, A., Kalinsky, K., McShane, L. M., … DeMichele, A. (2022). Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201063.
- Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
  Gradishar, W. J., Moran, M. S., Abraham, J., Aft, R., Agnese, D., Allison, K. H., … Kumar, R. (2022). Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 20(6), 691–722.
- Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
  Dixon-Douglas, J., Loibl, S., Denkert, C., Telli, M., & Loi, S. (2022). Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, 42, 1–13.
- Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer.
  Telli, M. L., Tolaney, S. M., Shapiro, G. I., Middleton, M., Lord, S. R., Arkenau, H. T., … Plummer, R. (2022). Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. NPJ Breast Cancer, 8(1), 45.
- Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A.
  Freedman, R. A., Graff, S. L., Somerfield, M. R., Telli, M. L., Wolff, A. C., & Giordano, S. H. (2022). Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(7), 516–519.
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
  Miles, D., Gligorov, J., André, F., Cameron, D., Schneeweiss, A., Barrios, C., … O'Shaughnessy, J. (2021). Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 32(8), 994–1004.
- A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
  Gruber, J. J., Afghahi, A., Timms, K., DeWees, A., Gross, W., Aushev, V. N., … Telli, M. L. (2022). A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nature Cancer.
- Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization.
  Zhou, R., Kozlov, A., Chen, S.-T., Okamoto, S., Ikeda, D. M., DeMartini, W., … Itakura, H. (2022). Harnessing artificial intelligence to automate delineation of volumetric breast cancers from magnetic resonance imaging to improve tumor characterization. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer.
  Mantz, A. B., Zhou, R., Kozlov, A., DeMartini, W., Chen, S.-T., Okamoto, S., … Itakura, H. (2022). Radiomic features quantifying pixel-level characteristics of breast tumors from magnetic resonance imaging predict risk factors in triple-negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer.
  Timms, K., Lenz, L., Cogan, E. S., Mayer, E. L., Kaklamani, V. G., Stearns, V., … Telli, M. L. (2022). Exploring homologous recombination deficiency thresholds for predicting response to platinum-based treatment in triple negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
  Gupta, T., Vinayak, S., & Telli, M. (2022). Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Research and Treatment.
- Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
  Geyer, C. E., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., … Tutt, A. N. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology.
- Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
  Schram, A. M., Colombo, N., Arrowsmith, E., Narayan, V., Yonemori, K., Scambia, G., … Yap, T. A. (2022). Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA Oncology.
- Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.
  Yap, T. A., Bardia, A., Dvorkin, M., Galsky, M. D., Beck, J. T., Wise, D. R., … Konstantinopoulos, P. A. (2022). Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncology.
- Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer.
  Ransohoff, J. D., Ritter, V., Purington, N., Andrade, K., Han, S., Liu, M., … Kurian, A. W. (2023). Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer. Nature Communications, 14(1), 2053.
- TRIAL IN PROGRESS: A PHASE 1 FIRST-IN-HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES
  Haber, T., Symons, J., Dharmadhikari, B., Mueller, T., Thakkar, D., Rodon, J. A., … Boyd-Kirkup, J. (2022). TRIAL IN PROGRESS: A PHASE 1 FIRST-IN-HUMAN STUDY OF HMBD-002, AN IGG4 MONOCLONAL ANTIBODY TARGETING VISTA, AS A MONOTHERAPY AND COMBINED WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES. JOURNAL FOR IMMUNOTHERAPY OF CANCER. BMJ PUBLISHING GROUP.
- NCCN Guidelines Insights: Breast Cancer, Version 4.2023.
  Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., … Kumar, R. (2023). NCCN Guidelines Insights: Breast Cancer, Version 4.2023. Journal of the National Comprehensive Cancer Network : JNCCN, 21(6), 594–608.
- Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study.
  Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Blum, J. L., Mina, L. A., … Telli, M. L. (2023). Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study. The Oncologist.
- A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).
  Turner, N. C., Balmana, J., Fasching, P. A., Hurvitz, S. A., Telli, M. L., Visco, F., … Robson, M. E. (2015). A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes.
  Lenz, L., Neff, C., Solimeno, C., Cogan, E. S., Abramson, V. G., Boughey, J. C., … Timms, K. M. (2023). Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes. Breast Cancer Research and Treatment.
- A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors
  Ahnert, J. R., Gruber, J. J., Telli, M. L., Mita, M. M., Mita, A. C., Kim, J. W., … Boyd-Kirkup, J. D. (2023). A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants.
  Zhang, M., Liu, W., Li, A., Htet, M. H., Yu, R., Telli, M. L., & Wu, J. C. (2023). Generation of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA2 variants. Stem Cell Research, 72, 103219.
- Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
  Testa, S., Dickerson, J. C., & Telli, M. (2023). Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan. CURRENT PROBLEMS IN CANCER: CASE REPORTS, 11.
- Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations.
  Zhang, M., Venkateshappa, R., Li, A., Fowler, M. B., Telli, M. L., & Wu, J. C. (2023). Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations. Stem Cell Research, 73, 103246.
- Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study.
  Turner, N. C., Laird, A. D., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., … Robson, M. E. (2023). Genomic analysis of advanced breast cancer tumors from talazoparib-treated gBRCA1/2mut carriers in the ABRAZO study. NPJ Breast Cancer, 9(1), 81.
- Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer family registry.
  Ransohoff, J. D., Miller, I., Koo, J., Joshi, V., Kurian, A. W., Allison, K. H., … Telli, M. L. (2024). Tumor-Infiltrating lymphocytes and breast cancer mortality in racially and ethnically diverse participants of the Northern California breast cancer family registry. JNCI Cancer Spectrum.
- Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
  Freedman, R. A., Caswell-Jin, J. L., Hassett, M., Somerfield, M. R., & Giordano, S. H. (2024). Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2400886.
- Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update.
  Burstein, H. J., DeMichele, A., Fallowfield, L., Somerfield, M. R., & Henry, N. L. (2024). Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 42(12), 1450–1453.
- Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status.
  Telli, M. L., Litton, J. K., Beck, J. T., Jones, J. M., Andersen, J., Mina, L. A., … Blum, J. L. (2024). Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status. Breast Cancer (Tokyo, Japan).
- Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
  Gradishar, W. J., Moran, M. S., Abraham, J., Abramson, V., Aft, R., Agnese, D., … Kumar, R. (2024). Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 22(5), 331–357.
- Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC)
  Harbeck, N., Barrios, C., Zhang, A., Saji, S., Jung, K. H., Hegg, R., … Mittendorf, E. (2024). Final analysis of the placebo-controlled randomised phase 3 IMpassion031 trial evaluating neoadjuvant atezolizumab (atezo) plus chemotherapy (CT) followed by open-label adjuvant atezo in patients (pts) with early-stage triple-negative breast cancer (eTNBC). ONCOLOGY RESEARCH AND TREATMENT. KARGER.
- VISTA-induced tumor suppression by a four amino acid intracellular motif.
  Zhao, Y., Andoh, T., Charles, F., Reddy, P., Paul, K., Goar, H., … Gruber, J. J. (2025). VISTA-induced tumor suppression by a four amino acid intracellular motif. BioRxiv : the Preprint Server for Biology.
- Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial.
  Cardoso, F., O'Shaughnessy, J., Liu, Z., McArthur, H., Schmid, P., Cortes, J., … Bardia, A. (2025). Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cancer: a randomized phase 3 trial. Nature Medicine.
- TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
  Telli, M. L., Gawryletz, C. D., Wei, M., Patnaik, A., Lu, D. R., Mazzoletti, M., … Mukohara, T. (2024). TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER plus /human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- Updates in HER2-Positive and Triple-Negative Breast Cancers
  Telli, M. L., & Gradishar, W. J. (2021). Updates in HER2-Positive and Triple-Negative Breast Cancers. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 19(5.5), 605–609.
- KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer
  Hirshfield, K., Cardoso, F., Bardia, A., Andre, F., Cescon, D., McArthur, H., … Karantza, V. (2020). KEYNOTE-756: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab or Placebo with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for High-Risk, Early-Stage, ER+/HER2-Breast Cancer. ANNALS OF SURGICAL ONCOLOGY. SPRINGER.
- JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts
  Yap, T. A., Konstantinopoulos, P., Telli, M. L., Saraykar, S., Beck, J. T., Galsky, M. D., … Bardia, A. (2020). JAVELIN PARP Medley, a phase 1b/2 study of avelumab plus talazoparib: Results from advanced breast cancer cohorts. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH.
- An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (<i>P</i>) in previously treated metastatic triple-negative breast cancer (mTNBC).
  O'Day, S., Borges, V. F., Chmielowski, B., Rao, R. D., Abu-Khalaf, M. M., Stopeck, A., … Graff, J. (2019). An open label, multicenter phase II study combining imprime PGG (PGG) with pembrolizumab (P) in previously treated metastatic triple-negative breast cancer (mTNBC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
  Cardoso, F., Bardia, A., Andre, F., Cescon, D. W., McArthur, H. L., Telli, M. L., … Karantza, V. (2019). KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
- TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial
  Vinayak, S., Tolaney, S. M., Schwartzberg, L. S., Mita, M. M., McCann, G. A.-L., Tan, A. R., … Telli, M. L. (2018). TOPACIO/Keynote-162: Niraparib plus pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer.
  Quist, J., Mirza, H., Cheang, M. C. U., Telli, M. L., Lord, C. J., Tutt, A. N. J., & Grigoriadis, A. (2017). Association of a four-gene decision tree signature with response to platinum-based chemotherapy in patients with triple negative breast cancer. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO).
  Turner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E.-M., … Robson, M. E. (2017). Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).
  DeMichele, A., Harding, J. J., Telli, M. L., Munster, P. N., McKay, R., Iliopoulos, O., … Infante, J. R. (2016). Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)
  Parton, M., Bardia, A., Kummel, S., Estevez, L. G., Huang, C.-S., Castan, J. C., … Kim, S.-B. (2015). A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY.
- Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer
  Telli, M. L. (2013). Insight or Confusion: Survival After Response-Guided Neoadjuvant Chemotherapy in Breast Cancer. JOURNAL OF CLINICAL ONCOLOGY, 31(29), 3613–3615.
- Assessment of Extent of Disease in Primary Breast Cancer
  Telli, M. L., & Guardino, A. E. (2011). Assessment of Extent of Disease in Primary Breast Cancer. BREAST SURGICAL TECHNIQUES AND INTERDISCIPLINARY MANAGEMENT, 263–268.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Open Trials Closed Trials

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.

A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

PALbociclib CoLlaborative Adjuvant Study

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

A Study of ABT-165 in Subjects With Solid Tumors

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

(VELA) Study of BLU-222 in Advanced Solid Tumors

Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)

Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

A Phase 1/2 Trial of ARV-471 Alone and in Combination with Palbociclib (IBRANCE®) in Patients with ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

18F-FSPG PET/CT for Cancer Patients on Therapy

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors

Specializing In

Practice Locations

Breast Cancer Program in Palo Alto Palo Alto, CA

Palo Alto, CA

Breast Cancer Program in Palo Alto

900 Blake Wilbur Dr, Fl 1

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Stanford Women's Cancer Center Palo Alto, CA

Palo Alto, CA

Stanford Women's Cancer Center

900 Blake Wilbur Dr, Fl 1

Palo Alto , CA 94304

(650) 498-6000

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(49 Ratings)

Overall Rating

5.0/5

View Ratings by Category

5.0/5

Friendliness

5.0/5

Explanations

5.0/5

Listens

4.9/5

Care provider's efforts to include you in decisions about your care

5.0/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(183 reviews)

Dr.Telli is exceptional in all aspects of doctoring - brilliant, informative, respectful, kind, patient, and very reassuring and comforting. Dr.Telli exudes confidence and gains ones trust immediately. I, honestly, feel healed in her presence even when not physically with her. I am most grateful to have her as my Oncologist. She is a 10 STAR doctor, in my opinion.

Dec 2024

•

Verified SHC Patient

Dr Telli is very caring and always has time to get an update on my life so she has the full picture.

Dec 2024

•

Verified SHC Patient

Dr Telli is caring and takes time to explain treatment

Dec 2024

•

Verified SHC Patient

She was super. Very kind, caring, smart, and helpful. She explained everything fully.

Nov 2024

•

Verified SHC Patient

Always very knowledgeable, thorough, compassionate, and informative. In additional, spends ample time discussing my needs and questions.

Oct 2024

•

Verified SHC Patient

Outstanding

Jul 2024

•

Verified SHC Patient

She is an amazing, patient, knowledgeable and compassionate physician. She is very thorough. I really like working with her.

Jun 2024

•

Verified SHC Patient

Dr Telli is very knowledgeable, she explains things well and have a kind bedside manner. She is patient and caring makes me feel comfortable.

May 2024

•

Verified SHC Patient

I am a 19 year breast cancer patient and Dr Telli was among the very best that I have as a part of my care!

Apr 2024

•

Verified SHC Patient

Dr Telli is just wonderful. Very thorough with her explanations. She wants all your questions answered. Thank you.

Apr 2024

•

Verified SHC Patient

Dr. Telli is amazing.

Mar 2024

•

Verified SHC Patient

Dr. Telli and her team are thorough, patient, and excellent. I never mind waiting a little because she gives me her full attention, is detailed in her explanations and questions, and always reassures me. I also had a great experience with her fellow Maggie Zhou, who made me feel heard and comfortable. I love my oncology team so much!

Feb 2024

•

Verified SHC Patient

I left the meeting with Dr. Telli energized, feeling confident and looking forward to a superior team experience as I fight cancer. She spent a thoughtful amount of time going over my unique circumstances and giving proactive commentary of future benefits I could participate in as well as confidence in my current trajectory.

Jan 2024

•

Verified SHC Patient

Very good Doctor very friendly

Dec 2023

•

Verified SHC Patient

Dr Melinda Telli and her staff are the best!

Dec 2023

•

Verified SHC Patient

Thanks again for taking the time. It was very helpful

Nov 2023

•

Verified SHC Patient

Compassionate, caring, expert, gave information about future trials, shared my joy at the good scan

Oct 2023

•

Verified SHC Patient

Melinda Telli is very thorough and listens to her patients concerns

Oct 2023

•

Verified SHC Patient

Excellent

Oct 2023

•

Verified SHC Patient

Melinda is brilliant, and at the cutting edge of the new protocols in the cancer teatment I am recieving. I am very grateful to have met her through a referral from a Nurse at Dominican Out Patient Oncology Unit in Santa Cruz. I totally think she understands the harshness of Chemo and felt comfortable making a plan that will treat the cancer and support me as a patient. TY DR Melinda Telli

Sep 2023

•

Verified SHC Patient

She came exceptionally prepared re: my med history and wanted more! I was impressed and was grateful for her time.

Sep 2023

•

Verified SHC Patient

Dr. Telli is a great doctor.

Aug 2023

•

Verified SHC Patient

It was just a check in and we will follow it up as test results come in

Aug 2023

•

Verified SHC Patient

she is very nice and helpful

Aug 2023

•

Verified SHC Patient

Dr. Telli and her colleague were great once I got to see them but it was over an hour wait.

May 2023

•

Verified SHC Patient

Excellent explanations and very empathtoc

May 2023

•

Verified SHC Patient

Dr. Telli was very informative and was familiar with my healthcare. She is very personable and explained things without going too fast. I felt very good after our appointment.

May 2023

•

Verified SHC Patient

Every step of this process was thorough and well-communicated. I felt very well taken care of.

May 2023

•

Verified SHC Patient

Excellent listener and very caring, lovely bed side manner. A fantastic doctor!

Mar 2023

•

Verified SHC Patient

The quality of the medicine practiced by Dr. Telli and her team is greatly appreciated. They take the time and put in a real effort to educate and reassure me.

Mar 2023

•

Verified SHC Patient

From the moment I met her, I felt that is was in excellent hands. Dr. Telli's reputation precedes her, but in addition to expertise she is also very caring and sensitive to her patients needs.

Feb 2023

•

Verified SHC Patient

Outstanding!

Feb 2023

•

Verified SHC Patient

I think she is a great doctor. So easy to talk to and feel very relax.

Jan 2023

•

Verified SHC Patient

Thanks to take the time to see me

Jan 2023

•

Verified SHC Patient

Dr. Telli was very informative, answered all questions, and has a personable demeanor.

Dec 2022

•

Verified SHC Patient

I was thrilled to see my oncologist once again

Dec 2022

•

Verified SHC Patient

I love her. So patient and kind and very clear.

Oct 2022

•

Verified SHC Patient

Dr Telli's expertise and kind encouragement were invaluable

Oct 2022

•

Verified SHC Patient

Dr Telli is awesomely wonderful.

Jul 2022

•

Verified SHC Patient

I really appreciated Dr. Telli's thoughtful insights about my case and potential treatment options, pending further data. She was compassionate and also pointed out resources that could provide psychological / emotional support when dealing with a new diagnosis, which sound helpful.

Jun 2022

•

Verified SHC Patient

Dr Telli is a wonderful doctor. She always takes the time to explain things and is very caring

May 2022

•

Verified SHC Patient

As a doctor I only consulted with, I felt she cared about my case and my health and made herself available for follow up. I am so grateful I found her and I highly value her opinion and recommendations for my treatment and care.

May 2022

•

Verified SHC Patient

Dr. Telli was most helpful and, above all, she spoke slowly and distinctly as she described my cancerous breast and the likely treatment. I appreciated her mentioning I could call her back with questions if they arise.

May 2022

•

Verified SHC Patient

Dr. Telli is the very best. She is calm, patient and very knowledgeable. Although I often have to wait some time to see her, she is well worth the wait. She does not rush me. I feel I have her undivided attention. During in office visits she is so very gentle. She has a touch like a butterfly. I feel so very fortunate to have her for my doctor.

Apr 2022

•

Verified SHC Patient

I have been well pleased with my cancer treatment at Stanford. Dr. Telli and her team have certainly made my experience with cancer a positive one~so much care and compassion with every appointment .

Apr 2022

•

Verified SHC Patient

terrific doctor

Apr 2022

•

Verified SHC Patient

Telli is wonderful, truly amazing combination of smart and kind. She also goes out of her way to teach her patients what is going on, which I've never had before (and I've met many oncologists). She has wonderful bedside manner and she's brilliant

Mar 2022

•

Verified SHC Patient

Although I was initially disturbed by not knowing what to do about the timing, The wait was very much worth it. When Dr Telli called It was more than worth the wait. Her information was very clear. She addressed all my concerns and suggested a path forward that was very comfortable for me. I am very very grateful that she made the time to talk to me. It was not rushed and even though she was extremely busy I felt I had her full attention. I also wish to compliment her associate(I'm sorry I forgot her name) that got our visit started. She also took her time with me. Overall if you could somehow sort out the process issues when an appointment is delayed everything is perfect. Excellent experience !!

Mar 2022

•

Verified SHC Patient

Dr Telli is the best.

Feb 2022

•

Verified SHC Patient

Dr. Telli is wonderful, caring and compassionate.

Feb 2022

•

Verified SHC Patient

Very helpful and professional

Feb 2022

•

Verified SHC Patient

She is the very best--cream of the crop. I feel so blessed to have her as my oncologist. She has a wonderful way with patients. She is very kind, patient and attentive. I trust her implicitly. Although I have to wait sometimes for her, the wait is well worth it. Did I make it clear that she is the very best!?!

Jan 2022

•

Verified SHC Patient

Melinda Telli is so knowledgeable and while I watched her present in Texas to other doctors and didnâ€™t understand a lot of what they were saying, she was able to break down her recommendation for my treatment in words I could understand. I am so thankful for Dr. Telliâ€™s advice and help with my treatment!

Dec 2021

•

Verified SHC Patient

Only one comment. She is an outstanding physician and communicator.

Dec 2021

•

Verified SHC Patient

Dr. Telli is the best!

Oct 2021

•

Verified SHC Patient

Dr Telli is a brilliant and compassionate breast oncologist. I'm very grateful to have her leading my care!!!

Sep 2021

•

Verified SHC Patient

Dr. Telli needs a bonus! So does Stanford Cancer Center. I am an experienced healthcare provider with high expectations. This team has exceeded all my expectations for care. I have told Dr. Telli this. She is an asset to Stanford Medicine and truly cares for and about her patients. A passion for what she does. Rare to find in a lot of physicians these days. I feel fortunate to have had her during a journey I did not expect to be on. STANFORD should do everything in their power to retain her and her staff for years to come. A great physician and beautiful human being.

Sep 2021

•

Verified SHC Patient

Dr. Telli was personable, clearly explained everything, and was efficient with the time we had together. I'm very grateful I was able to consult with her.

Aug 2021

•

Verified SHC Patient

Dr Telli is excellent. I have full confidence in her care and my plan moving forward.

Aug 2021

•

Verified SHC Patient

She was very personable, took her time explaining things and answered all of my questions to my satisfaction.

Jun 2021

•

Verified SHC Patient

Dr Telli is amazing!

May 2021

•

Verified SHC Patient

I recommend stanford every opportunity i have

May 2021

•

Verified SHC Patient

I very highly recommend Dr Telli! She is my hero!

May 2021

•

Verified SHC Patient

Dr. Telli is fabulous.

Dec 2020

•

Verified SHC Patient

Dr. Telli is a very caring doctor and has very good bedside manner.

Nov 2020

•

Verified SHC Patient

Dr. Telli is the best!

Oct 2020

•

Verified SHC Patient

Dr. Telli has been wonderful. While I would like to not have to recommend her but if I had any friend or family member who needs to see an oncologist I would recommend her without hesitation.

Jul 2020

•

Verified SHC Patient

Dr. Telli is an excellent doctor. I am so glad to have her as my oncologist!

Jul 2020

•

Verified SHC Patient

Dr. Telli is a very good and caring physician. She has never rushed me and always answers my questions. I highly recommend her.

Jun 2020

•

Verified SHC Patient

Melinda Telli is great caring, thorough and easy to talk to.

Mar 2020

•

Verified SHC Patient

Dr. Telli is incredibly caring & warm. She listens well & is thorough on her examination & explanations.

Jan 2020

•

Verified SHC Patient

Dr. Telli is so calm, friendly & warm, even when very busy, she spends the time needed. Remembers me when I come in, so knowledgeable. I travel from out of state to see her & it is well worth it!

Jan 2020

•

Verified SHC Patient

Dr. Telli is fabulous!

Dec 2019

•

Verified SHC Patient

These ratings are for Dr. Melinda Telli.

Dec 2019

•

Verified SHC Patient

Dr. Telli is wonderful. Very knowledgeable & caring. I have utmost confidence in her.

Dec 2019

•

Verified SHC Patient

Dr. Telli is amazing. Her knowledge of the latest cancer research, her attention to detail saved my life. I love Dr. T.

Dec 2019

•

Verified SHC Patient

Very thorough. Very patient with my questions. Very knowledgeable. I travel far to see her but it is worth it.

Nov 2019

•

Verified SHC Patient

Dr. Telli is kind, caring, and takes time to address all issues. I travel from out of state to see her and it is well worth it.

Nov 2019

•

Verified SHC Patient

Dr. Telli is fabulous! I feel she genuinely cares about me.

Jun 2019

•

Verified SHC Patient

Dr. Telli is remarkable. I would describe her as a "Stanford Brilliant." She is a master at her craft.

Jun 2019

•

Verified SHC Patient

Dr. Telli is an excellent doctor with great bedside manner. I am very lucky she is my doctor.

May 2019

•

Verified SHC Patient

The provider was calm, respectful, & informative. She was very clear explaining options to me. I didn't feel rushed & believe she gave me her utmost attention.

May 2019

•

Verified SHC Patient

Very nice care, loving kindness, willing to listen. Patiently explain.

Apr 2019

•

Verified SHC Patient

Dr. Telli and Kiran were an excellent team. They were both compassionate, respectful and extremely competent. I have never been more pleased with a medical appointment. I felt listened to, and they had innovative therapy for me to try. They spent plenty of unhurried time with me. Excellent appointment!

Mar 2019

•

Verified SHC Patient

I highly recommend Dr. Telli & Erin (PA). They are both awesome.

Mar 2019

•

Verified SHC Patient

Dr. Telli and her staff are amazing. They made us feel like people not a number. She spent time with us and explained things in a way we could understand.

Feb 2019

•

Verified SHC Patient

Dr. Telli is the best!

Feb 2019

•

Verified SHC Patient

I was extremely impressed with the patience, care, and genuine attentiveness that Dr. Telli showed during my appointment. This is especially true since she entered my room around 7 p.m. and stayed for an hour, and I'm sure she had already had a long, busy day.

Dec 2018

•

Verified SHC Patient

Dr. Telli is an excellent physician.

Dec 2018

•

Verified SHC Patient

Dr. Telli is a VERY caring genuine professional. Makes you feel very comfortable explains thing very clearly so I understand it.

Nov 2018

•

Verified SHC Patient

Dr. Telli is very knowledgeable & compassionate. I feel confident w/her.

Oct 2018

•

Verified SHC Patient

Dr. Telli is a great doctor with a very good bedside manner. I highly recommend her.

Sep 2018

•

Verified SHC Patient

Dr. Telli was head and shoulders better than any of the other 3 oncologists I have met with.

Sep 2018

•

Verified SHC Patient

Really appreciate how thorough Dr. Telli is. So knowledgeable as well.

Sep 2018

•

Verified SHC Patient

Dr. Telli is extremely caring and present during my appointment(s). I have the utmost confidence in her!! Thank you for your excellence in all areas, Dr. Telli!

Aug 2018

•

Verified SHC Patient

Dr. Telli is excellent.

Aug 2018

•

Verified SHC Patient

Dr. Telli is fabulous.

Jul 2018

•

Verified SHC Patient

Dr. Telli was amazing, every thing I had hoped for and more. I left her office with valuable information & hope. PA Erin was also awesome. So thankful for my Stanford visit.

Jul 2018

•

Verified SHC Patient

Doc was wonderful, very informative.

Jul 2018

•

Verified SHC Patient

Both Dr. Telli & NP were thorough, friendly, & informative.

Jul 2018

•

Verified SHC Patient

I love Dr. Telli she is the absolute BEST!!

Jul 2018

•

Verified SHC Patient

I love Melinda Telli and Jessica Foran. The CARE they show for me is unbelievable.

Jun 2018

•

Verified SHC Patient

Everyone is so nice. Friendly and professional.

May 2018

•

Verified SHC Patient

Dr. Telli was not only personable but thorough.

May 2018

•

Verified SHC Patient

Dr. Telli always takes good care of me. She has very good bedside manner. She's a great doctor.

May 2018

•

Verified SHC Patient

I had an excellent team of care providers at Stanford.

Mar 2018

•

Verified SHC Patient

I'm so happy having Dr. Telli as my breast oncologist cause she's so compassionate & understanding with untiring efforts to heal me with her patience that helps me continue with my fight against cancer. My appreciation & eternal gratitude to her! Thanks very much.

Mar 2018

•

Verified SHC Patient

I appreciated the amount of information given to me. Almost all my questions were answered before I asked them.

Feb 2018

•

Verified SHC Patient

Dr. Telli and team were very attentive explained everything in detail and made me feel comfortable.

Feb 2018

•

Verified SHC Patient

Dr. Telli is amazing! Could not have asked for any better care.

Nov 2017

•

Verified SHC Patient

Dr. Telli is an excellent care provider.

Oct 2017

•

Verified SHC Patient

Dr. Telli is a gem. I feel blessed to have her on my team.

Oct 2017

•

Verified SHC Patient

Best physician I have ever had.

Sep 2017

•

Verified SHC Patient

Dr. Telli is a very good doctor with a very caring bed-side manner. I highly recommend her.

Sep 2017

•

Verified SHC Patient

Excellent provider but needed to wait 2 hrs. for visit.

Aug 2017

•

Verified SHC Patient

Jessica Foran and Melinda Telli are superlative givers of care. I cannot express how positively they have both impacted my life during and post cancer treatment.

Apr 2017

•

Verified SHC Patient

Dr. Telli was so thorough & professional. She took her time and answered all my questions. She was able to provide studies to reinforce her recommendations for my care.

Feb 2017

•

Verified SHC Patient

I love the dr.!!!

Feb 2017

•

Verified SHC Patient

Excellent care in explaining options that were easy to understand and explaining details and status of my prognosis.

Jan 2017

•

Verified SHC Patient

Excellent physician!

Jan 2017

•

Verified SHC Patient

Dr. Telli is professional, warm, and caring - an IDEAL care provider!

Jan 2017

•

Verified SHC Patient

Have always had good experiences/contacts at this facility.

Jan 2017

•

Verified SHC Patient

Dr. Telli, Josh and Pei-ter are a great and compassionate team.

Jan 2017

•

Verified SHC Patient

Dr. Telli is the best physician - she explained - everything thoroughly and was very patient.

Dec 2016

•

Verified SHC Patient

Dr. Telli provides reassurance and is very knowledgeable on treatment of breast cancer.

Dec 2016

•

Verified SHC Patient

Dr. Telli is the most compassionate and kind doctor I have ever met.

Nov 2016

•

Verified SHC Patient

Dr. Melinda Telli is a saint - no, really!!

Oct 2016

•

Verified SHC Patient

They make me feel confident in asking about any concern I have.

Oct 2016

•

Verified SHC Patient

Dr. Telli is a fantastic doctor. She has a very good bedside manner and very caring.

Oct 2016

•

Verified SHC Patient

Love Dr. Telli!

Oct 2016

•

Verified SHC Patient

Very caring, outstanding doctor.

Oct 2016

•

Verified SHC Patient

Thanks to these doctors, this place and their care I'm still alive. Thank you.

Sep 2016

•

Verified SHC Patient

I needed to discuss doctor's recommendation in more detail and to ask several significant questions. The follow-up by doctor after the appt. was poor.

Sep 2016

•

Verified SHC Patient

Dr. Telli always provides a complete evaluation, not just related to the purpose of the visit. She is the perfect blend of the art and science of medicine.

Aug 2016

•

Verified SHC Patient

Dr. Telli is great!

Aug 2016

•

Verified SHC Patient

Explained things very clearly. Drew diagrams to explain.

Aug 2016

•

Verified SHC Patient

Dr. Telli is a truly wonderful physician. She has genuine care and concern and we are very grateful to be in her care.

Jul 2016

•

Verified SHC Patient

Dr. Telli is wonderful and her fellow is equally as talented.

Jul 2016

•

Verified SHC Patient

Dr. Telli very compassionate & kind. Very thorough.

Jun 2016

•

Verified SHC Patient

Dr. Telli is excellent, as are Greg (her intern) Larissa & Kiran. All very good at explaining my diagnosis, medications & what to expect!

Jun 2016

•

Verified SHC Patient

Good.

May 2016

•

Verified SHC Patient

Dr Telli and staff are wonderful. Well worth the drive from Reno!

May 2016

•

Verified SHC Patient

Exceptionally high level of compassion; provided a very clear rationale for next steps in my medical care.

Apr 2016

•

Verified SHC Patient

Dr. Telli is technically an excellent oncologist, but the human side of her approach puts her in a completely different class of other doctor's I've encountered. She is truly spectacular.

Apr 2016

•

Verified SHC Patient

Dr. Telli and her associate spent a good deal of time w/ me in examination, analysis and preparation of a Tx. plan, and later in their explanations of this plan. I had a very good experience w/ Dr. Telli and her team.

Apr 2016

•

Verified SHC Patient

Dr. Telli and Larissa are the best. My husband felt so well informed & supported he said he wish that he had had a tape of the conversation.

Apr 2016

•

Verified SHC Patient

Dr. Telli is professional, caring. Very happy to have her on my corner.

Apr 2016

•

Verified SHC Patient

Dr. Telli is by far the finest doc. I have ever dealt with as cared for by heaps of empathy and delightful person! I have considerable experience with Stanford across several disciplines - She is THE BEST.

Apr 2016

•

Verified SHC Patient

I love Dr. Telli - she saved my life.

Mar 2016

•

Verified SHC Patient

Dr. Telli is great. She also has a wonderful touch. We (my husband comes with) travel quite a ways to see her.

Mar 2016

•

Verified SHC Patient

I have much confidence in Doctor Telli, Melinda because she doesn't leave me without treatment.

Mar 2016

•

Verified SHC Patient

These "very good" are all true. Dr.Waprin & Dr.Telli & their staff were terrific.

Mar 2016

•

Verified SHC Patient

Dr Telli is fantastic care provider. I highly recommend her and thankful to have her as my Oncologist after a long search.

Mar 2016

•

Verified SHC Patient

Extremely informative & pleasant -

Feb 2016

•

Verified SHC Patient

Dr. Telli excellent.

Dec 2015

•

Verified SHC Patient

Both Dr. Telli and Dr. Afghahi are helpful and willing to discuss any questions I have. I am in a clinic trial with them but wish I were able to transfer all of my care. However, distant makes that impossible.

Nov 2015

•

Verified SHC Patient

Dr. Telli is an amazing doctor!! I can't say enough good about her.

Sep 2015

•

Verified SHC Patient

Wonderful experience.

Sep 2015

•

Verified SHC Patient

This was the first time I had met Dr. Telli. I found her to be very knowledgeable, professional, caring, intelligent, clear and pleasant to deal with.

Aug 2015

•

Verified SHC Patient

I feel comfortable and I have trust in Dr. Telli, which gives me peace of mind.

Jul 2015

•

Verified SHC Patient

My team take very good care of me.

Jul 2015

•

Verified SHC Patient

Extremely pleased with Dr. Telli & Stanford on the whole.

Jun 2015

•

Verified SHC Patient

Dr. Telli is amazing. So professional, yet compassionate and encouraging.

May 2015

•

Verified SHC Patient

Dr. Melinda Telli has just the right balance of intelligent, specific knowledge and the ability to convey it in terms we could understand. Great "bedside" manner. TOTALLY professional.

May 2015

•

Verified SHC Patient

I always feel fully satisfied that I have been completely understood & given excellent treatment.

May 2015

•

Verified SHC Patient

Excellent Dr. Telli is the BEST.

Apr 2015

•

Verified SHC Patient

Dr. Telli is what every Dr. should be. She is wonderful.

Mar 2015

•

Verified SHC Patient

Dr. Telli is an excellent care provider, very knowledgeable, up-to-date, caring, easy to understand.

Feb 2015

•

Verified SHC Patient

She is my life line to emotional and health care.

Oct 2014

•

Verified SHC Patient

Dr. Telli is very kind, informative and empathetic. She has an excellent bedside manner.

Oct 2014

•

Verified SHC Patient

Dr. Telli should be cloned - all drs. should be her. She is wonderful!

Sep 2014

•

Verified SHC Patient

Good experience.

Aug 2014

•

Verified SHC Patient

Dr. Telli was wonderful. I came to her for a second opinion and she was much more helpful than my regular doctor.

Aug 2014

•

Verified SHC Patient

Dr. Melinda Telli is exceptional. I would never go back to my previous oncologist. I totally trust her & think she's an outstanding doctor.

Aug 2014

•

Verified SHC Patient

Dr. Telli is an amazing listener, a warm & engaging person, & solution-focused.

Jun 2014

•

Verified SHC Patient

Dr. Telli made decision for treatment & explained why.

Jun 2014

•

Verified SHC Patient

Dr. Telli spent quality time with me and covered all my concerns. I felt very comforted by her manner and knowledge.

May 2014

•

Verified SHC Patient

My provider is great!! Always makes me feel I am HER main concern - And my total well being - Not just the cancer.

May 2014

•

Verified SHC Patient

Dr. Telli is everything we hoped for & more.

May 2014

•

Verified SHC Patient

I love Melinda Telli and all of her staff -- She is a very compassionate doctor & spends a great deal of time w/me.

May 2014

•

Verified SHC Patient

Both the PA & Dr. Telli were very clean & helpful in explaining options to me.

Feb 2014

•

Verified SHC Patient

Dr. Telli and her staff are the best!

Jan 2014

•

Verified SHC Patient

Very good.

Jan 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Melinda L. Telli, M.D.

Medical oncologist, Breast specialist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Breast Cancer Program in Palo Alto Palo Alto, CA

Breast Cancer Program in Palo Alto

Stanford Women's Cancer Center Palo Alto, CA

Stanford Women's Cancer Center

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(183 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Melinda L. Telli, M.D.

Medical oncologist, Breast specialist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Memberships

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Breast Cancer Program in Palo Alto Palo Alto, CA

Breast Cancer Program in Palo Alto

Stanford Women's Cancer Center Palo Alto, CA

Stanford Women's Cancer Center

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(183 reviews)

Referring Physicians

PHYSICIAN HELPLINE